INTRODUCTION
BCOR was originally identified via its interaction with the site-specific DNA-binding transcription factor BCL6, whose aberrant expression drives formation of diffuse large B-cell lymphomas.
1,2 BCOR is likely to be a crucial mediator of BCL6 function in these cancers. 3 By contrast, recurrent somatic BCOR mutations have been identified in human cancers, including retinoblastoma, medulloblastoma, osteosarcoma and hepatocellular carcinoma, [4] [5] [6] [7] [8] suggesting that BCOR can also function as a tumor suppressor protein. Using whole-exome sequencing, we and others have recently detected somatic BCOR mutations in acute myelogenous leukemia with normal karyotypes (CN-AML, 3.8%), myelodysplastic syndrome (MDS, 4.2%) and chronic myelomonocytic leukemia (7.4%) and found that these mutations are associated with a poor prognosis. 9, 10 Recent reports showed the presence of somatic mutations of BCOR in acquired aplastic anemia. 11, 12 However, knowledge of the role that BCOR plays in normal hematopoiesis is limited and its potential function as a tumor suppressor in hematopoietic transformation is largely unknown.
The X-linked BCOR gene is essential for human development. 13 Female patients harboring heterozygous mutations in BCOR develop oculofaciocardiodental syndrome. Peripheral blood lymphocytes from oculofaciocardiodental patients show strongly biased inactivation of the X chromosome harboring the mutant BCOR allele, 13 suggesting that BCOR is required for normal hematopoiesis. Furthermore in mice, BCOR appears to play a role in differentiation of primitive erythroid and lymphoid cells. 14 BCOR is found in a multisubunit complex with mammalian homologs of Polycomb group (PcG) proteins. [15] [16] [17] PcG genes were originally identified in Drosophila melanogaster as negative regulators of Hox genes. 18 PcG protein homologs are involved in many biological processes in mammals, including maintenance of stem cell identity, differentiation and cancer development, [19] [20] [21] and are involved in various cellular functions including posttranslational histone modification and chromatin compaction. 22 Polycomb Repressive Complex-1 (PRC1) and -2 (PRC2) are the two main PcG complexes, which catalyze repressive histone modifications: monoubiquitination of histone H2A at lysine-119 (H2AK119ub) and methylation of histone H3 at lysine-27 (H3K27me), respectively. 20, [23] [24] [25] At least six mammalian PRC1 complexes (PRC1.1-PRC1.6) have been identified that have different subunit compositions, but all contain the RING1A/B catalytic subunit(s). 17 BCOR is a component of the PRC1.1 complex that contains RING1A/B, PCGF1, RYBP/YAF2, SKP1 and KDM2B. 16, 17 The biological and functional relevance of the diversity of PRC1 complexes is an active area of investigation. Analysis of loss-or gain-of-function alleles of components of the PRC1 complex can provide insights into specific roles of that complex. Here, we have taken this approach to investigate the role of BCOR and thus PRC1.1 in hematopoiesis. We report that BCOR plays an important role in regulating hematopoietic cell proliferation and differentiation. BCOR is involved in maintaining RING1B protein abundance and regulates gene transcription through regulation of H2A ubiquitination. Our data indicate that BCOR provides an important link between transcriptional and epigenetic regulation that is required for myeloid cell proliferation and differentiation.
MATERIALS AND METHODS Mice
The details of the generation of the Bcor Fl allele will be described elsewhere (Hamline, Corcoran, Wamstad et al., in preparation). In brief, exons 9 and 10 of Bcor allele were flanked by LoxP sites to allow their removal via expression of CRE recombinase. Excision of these exons results in a frameshift and a premature stop codon causing nonsense-mediated decay and/or carboxy-terminal deletion of the BCOR protein. The details of the generation of the Rosa26 LsLmBcorA allele will be described elsewhere (Hamline, Corcoran, Wamstad et al., in preparation). In brief, a conditional (Lox-Stop-Lox) myc-tagged Bcor splice version A (mBcorA) expression cassette was inserted into the murine Rosa26 locus (Rosa26 LsLmBcorA ). mBcorA overexpression can be induced by CRE excision of the loxP-flanked Stop-cassette (LsL).
Cell culture, transfection and electroporation

Bcor
Fl/Y BM (bone marrow) cells were cultured in Iscove's modified Dulbecco's media (Invitrogen, Grand Island, NY, USA) with 20% fetal bovine serum plus 50 ng/ml stem cell factor, 25 ng/ml interleukin-6 (IL-6) and 10 ng/ml IL-3. HL60, NB4 and 293 T cells (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI-1640 medium plus 10% fetal bovine serum. HL60 and NB4 cells were transfected either with nontargeted siRNA or with siRNA against BCOR (Dharmacon, Lafayette, CO, USA; 5′-GGACTAACATCACTGAAGA-3) 3 using Amaxa Nucleofector Technology (Lonza, Iowa City, IA, USA), following the manufacturer's instructions. siGENOME siRNA smartpool targeting HoxA5, HoxA7 and HoxA9 (Dharmacon) were transfected into NIH3T3 cells (RNAimax; Invitrogen) as well as Control and Bcor Mutant cells (Amaxa Kit V, T-016 programe), following the manufacturers' instructions.
Retroviral constructs and transduction
Retroviral supernatants were produced by transfecting Platinum-E (Plat-E) cells with the retroviral constructs Cre-IRES-puro or Puro empty vector controls (Addgene, Cambridge, MA, USA) using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. At 24 and 48 h post transfection, the virus supernatants were collected and put through a 0.45-μm filter. Virus were loaded by centrifugation (2000 g, 90 min at 32°C) twice on 50 μg/ml RetroNectin (Takara, Shiga, Japan)-coated non-tissue culture six-well plates. Two to three million cells were transduced per well by centrifugation at 500 g for 30 min and maintained for 48 h at 37°C with 5% CO 2 before transferring into culture flasks. Transduced cells were selected with puromycin (3 μg/ml for 3 days).
Western blot and histone extraction
Cell lysate was separated on sodium dodecyl sulfate polyacrylamide gel electrophoresis gel (Bio-Rad, Hercules, CA, USA) and transferred to nitrocellulose membranes. After incubation with appropriate primary and secondary antibodies, the immunoblots were developed using SuperSignal Western blotting kits (Pierce Biotechnology, Rockford, IL, USA) and exposed to X-ray film. The following antibodies were used: BCOR, 16 RING1B (Cell Signaling Technology D22F2, Danvers, MA, USA), ubiquitin H2AK119 (Millipore 05-678, Temecula, CA, USA), H2A (Cell Signaling Technology #2578) and β-actin (Sigma A5316, St Louis, MO, USA). Endogenous ubH2A analysis was carried out following methods exactly as previously described. 26 
Chromation immunoprecipitation
Assays were performed using MAGnify Chromatin Immunoprecipitation System (Invitrogen) according to the manufacturer's protocol. Briefly, cells were fixed by formaldehyde. For each chromatin immunoprecipitation (ChIP) reaction, 2 × 10 6 cells were used. All resulting precipitated DNA samples were quantified with real-time PCR. Data were expressed as the percentage of input DNA. The primer sequences for Bcor and the ubiquitinated H2A-binding region of the HoxA5, HoxA7 and HoxA9 are indicated in Supplementary Table S1 .
Reverse transcription reaction and quantitative PCR Total RNA from cultured cells was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Two hundred nanograms of RNA were processed directly to cDNA by reverse transcription with qScript cDNA SuperMix following the manufacturer's instructions (Quanta Biosciences, Gaithersburg, MD, USA). Sequences for primers used in this study are listed in Supplementary Table S1 . We used SYBR Premix Ex Taq (Perfect Realtime; Takara Bio) for quantitative PCR according to the manufacturer's instructions.
RNA microarray and data analysis
Total RNA from either mouse cells or AML patients' mononuclear cells was isolated by RNeasy (Qiagen) purification, checked for quality using an Agilent Bioanalyser (Agilent Technologies, Santa Clara, CA, USA). RNA from murine cells was hybridized on Illumina MouseWG-6 beadchips. Raw expression data were obtained from the GenomeStudio software with the subtraction of the background. Prior to identification of differentially expressed genes, raw data were normalized based on the cross-correlation method. 27 Significant changes in gene expression were identified based on the average fold change cutoff of 1.5, and the cutoff of the false discovery rate corrected P-value cross all replicates at 0.05.
Total RNA from human AML patient samples with either WT or mutant BCOR identified by whole-exome sequencing 10 were hybridized on Affymetrix GeneChip HGU133 plus 2. The whole transcriptome gene level expression data were obtained by using the robust multichip average method, which is publically available in the 'affy' package of Bioconductor (https://www.bioconductor.org). Informed consent was obtained from all subjects and the study was approved by the ethics committee at Munich Leukemia Laboratory (MLL). All microarray data are available in the Gene Expression Omnibus (GEO, GSE69624).
For identification of enriched gene sets, Gene Set Enrichment Analysis (GSEA) was performed based on the normalized data and using GSEA v2.07 tool (http://www.broad.mit.edu/gsea/) with msigdb.v4.0.
Methylcellulose colony assay BM cells were added to methylcellulose containing growth factors (Methocult 3434, containing IL-3, IL-6 and stem cell factor; Stem Cell Technology, Vancouver, BC, Canada). The mixture was plated in triplicate cultures. Colonies were counted on days 6 and 12. For self-renewal experiments, the cells in the methylcellulose plate (mostly colonies) were diluted with phosphate-buffered saline, counted and replated on fresh methylcellulose and colony formation was observed and counted. Replatings were performed on day 10 of soft-gel culture. All experiments were done in triplicate.
Statistical analyses
The Student's t-test (unpaired t-test) was used to analyze statistical significance and normality tests were used to test the assumption of a normal distribution. GraphPad Prism software (La Jolla, CA, USA) was used for statistical calculations. Error was calculated using s.d. unless otherwise noted; *P o0.05, **Po0.01.
RESULTS
BCOR regulates myeloid cell proliferation
To determine the role of BCOR in myeloid cell proliferation and differentiation, we used both loss-of-function and overexpression approaches. First, we took advantage of a mouse conditional Bcor allele, Bcor Fl (Hamline, Corcoran, Wamstad et al., in preparation and see Materials and methods for a brief description). We isolated BM cells from Bcor Fl/Y animals and cultured these cells under myeloid stem/progenitor conditions (stem cell factor, IL-3 and IL-6). These Bcor Fl/Y BM cells were transduced with either a control empty retrovirus (hereafter 'control cells') or a retrovirusexpressing CRE recombinase to induce deletion of the floxed Bcor exons and generate the mutant allele (Bcor -/Y , hereafter 'Bcor mutant cells'). This mutant allele in which exons 9 and 10 are missing generates an mRNA with a premature stop codon. The resulting truncated protein is missing in the region required for interaction with the core PRC1 components 16, 28 and mimics the pathogenic mutations seen in oculofaciocardiodental patients. 13 Transduced cells were selected with 3 μg/ml puromycin for 3 days and subjected to further analysis. PCR confirmed DNA deletion and western blot showed the expression of the truncated BCOR ( Figure 1a) . In liquid culture, the Bcor mutant cells demonstrated 
BM cells from homozygous Rosa26
LsLmBcorA /Rosa26 LsLmBcorA mice were cultured under myeloid stem/progenitor conditions and infected with either a control or Cre expression retrovirus to induce Bcor overexpression (Figure 1d, left panel) . Transduced cells were selected with 3 μg/ml puromycin for 3 days and subjected to further analysis. The Bcor-overexpressing cells exhibited a profound decreased proliferative rate as measured in the methycellulose colony assay (Figure 1d ). Together, these results suggest that BCOR negatively regulates cell proliferation.
BCOR helps control myeloid cell differentiation To identify BCOR-regulated genes in myeloid cells, we used microarrays to compare global gene expression in control and Bcor mutant BM cells cultured for 7 days under myeloid stem/ progenitor conditions. Over 1200 genes were misregulated by greater than twofold (P o 0.05; Figure 2a In vivo, deletion of Bcor within the hematepoietic cells using Vav-iCre 31 led to an increase in peripheral blood neutrophils (Figure 2g ), but no significant changes occurred in RBC, platelet and lymphocyte levels in these mice (Supplementary Figure S1 ).
BCOR is a repressor of HoxA genes in myeloid cells PcG proteins are known repressors of Hox genes, and a recent study showed that polycomb group ring finger 1 (Pcgf1), 32 a member of the BCOR/BCORL1 complex, was involved in Hox gene expression regulation. We hypothesized that BCOR may alter expression of Hox and other PcG targets. Hox genes were highly enriched in Bcor mutant myeloid cells among the differentially expressed genes ( Figure 2a ) compared with control cells. We performed hierarchical cluster analysis of Hox genes present in differentially expressed genes set and showed HoxA5, HoxA7, HoxA9 and HoxB4 have the greatest fold changes in Bcor mutant cells (Figure 3a) . qRT-PCR confirmed that the expression level of HoxA5, HoxA7, HoxA9 and HoxB4 were upregulated in Bcor mutant cells (Figure 3b) , while Bcor-overexpressing cells had lower levels of the same set of Hox genes (Figure 3c) . GSEA among the differentially expressed genes (Figure 2a ) in control and Bcor mutant myeloid cells revealed that the expression of HoxA9 targets, 33, 34 proliferation-associated genes 35 and MYC target genes 36 were significantly enriched in cells with Bcor mutation (Figure 3d) . To demonstrate the significance of Hox genes as a target of BCOR, we knocked down HoxA5, HoxA7 and HoxA9 in control and Bcor mutant myeloid cells (Figure 3e ) and examined cell proliferation by methylcellulose BCOR affects RING1B protein levels and H2A ubiquitylation at HoxA loci BCOR is reported to associate with RING1B to form the PRC1.1 complex. 16, 17 Western blot analyses showed that RING1B protein levels are much lower in Bcor mutant myeloid cells and in myeloid differentiated cells, compared with control cells, respectively (Figures 4a and b ). In contrast, the level of Ring1b mRNA was unchanged (Figure 4c ). Therefore, BCOR protein abundance is correlated with RINGB1 protein abundance. This suggests that loss of BCOR protein, via either differentiation of wild-type cells or by genetic ablation in the progenitor population, can lead to a decrease in the RING1B protein abundance. Global levels of H2AK119ub were unchanged in the Bcor mutant cells (Figure 4e ). However, ChIP-quantitative PCR revealed that H2AK119ub levels at the promoters of HoxA5, HoxA7 and HoxA9 were significantly decreased in Bcor mutant cells (Figure 4f ). M, 5 days) treated HL60 and NB4 cells were used as positive controls for cell differentiation. (c) BCOR expression was compared by qRT-PCR (left) and western blot (right) in BM, NB4 and HL60 cells that were either untreated (con) or induced to differentiate by incubation with 50 μg/ml granulocyte colony-stimulating factor (GCSF) for 3 days (BM) or 10 − 7 M ATRA for 5 days (NB4 and HL60). *Po0.05, **Po0.01 (two-tailed, unpaired t-test).
Silencing BCOR induces myeloid cell differentiation of HL60 and NB4 cells To address further the role of BCOR in myeloid cell differentiation, we investigated whether silencing BCOR (by siRNA) affects cell differentiation in the human acute promyeloid leukemia cell lines, HL60 and NB4. 37, 38 BCOR knockdown was confirmed by qRT-PCR (Figure 5a , left) and western blot (Figure 5a, right) . Silencing of BCOR resulted in a dramatic increase in myeloid differentiation of HL60 and NB4 cells as measured by expression of CD11b (Figure 5b ). All-trans retinoic acid was used as a positive control for inducing differentiation ( Figure 5b ). As our results suggested that BCOR is implicated in suppressing myeloid cell differentiation, we compared its expression level in HL60 and NB4 cells induced to differentiate by all-trans retinoic acid and BM cells treated with or without granulocyte colony-stimulating factor, and found that BCOR RNA and protein levels were dramatically decreased upon cell differentiation (Figure 5c ). In agreement with our finding that BCOR decreases during myeloid differentiation, in silico analysis of normal human hematopoietic cells (Gene Enrichment Profiler, HemaExplorer) 39, 40 showed that BCOR levels are very high in longterm hematopoietic stem cells (HSCs) and its levels decrease with myeloid differentiation towards monocytes and granulocytes (nearly no expression).
Gene expression changes in Bcor mutant CD34+ cells are consistent with increased proliferation To investigate further the role of BCOR in early hematopoietic cells, we performed global gene expression profiling of CD34+ cells from control and Bcor mutant cells. A total of 130 genes were misregulated by greater than twofold (P o 0.05) (Figure 6a ). Congruent with our proliferation and colony assay results (Figure 1) , GSEA revealed that the expression of proliferation-associated genes 41 and MYC upregulated genes 36 was significantly enriched in Bcor mutant CD34+ cells (Figure 6b) .
Comparison of RNA expression in AML and MDS patients samples either with or without BCOR mutations Next, we investigated whether the results from our murine model are relevant to human MDS/AML with BCOR mutations. BCOR mutations occur in about 4% of chromosome normal (CN)-AML. 10 We compared global gene expression in de novo CN-AML male samples that were negative for NPM1, CEBPA, FLT3-ITD and MLL-PTD mutations and contained either WT BCOR or nonsense mutant BCOR (6 samples; Figures 7a-c and Supplementary Table 2 ). GSEA revealed that the expression of genes associated with myeloid cell differentiation 29 was significantly enriched in BCOR mutant samples, compared with control BCOR WT samples (Figure 7a ). On the other hand, genes associated with HSC 42 were depressed in the BCOR mutant samples (Figure 7b ). Genes upregulated in the BCOR mutant samples also showed significant enrichment with genes upregulated upon loss of BMI1, 43 a component of the PRC1.4 complex suggesting some functional overlap between PRC1.1 and PRC1.4 in AML (Figure 7c ). We collected 73 MDS patients BM samples having a normal karyotype either with or without a BCOR mutation (Supplementary Table 3) . qRT-PCR analysis in those samples revealed that expression of HOXA9 was upregulated significantly in MDS patients with BCOR loss-of-function mutations (Figure 7d ). In addition, we analyzed global gene expression in GEO data sets of 12 BCOR wild-type CN-AML cases and 12 BCOR mutated CN-AML cases (GSE30442). 10 Similar to our analysis of control and Bcor mutant murine myeloid cells ( Figure 6 ) and our patient samples (Figure 7) , GSEA of this data set demonstrated that BCOR mutant samples were enriched for proliferation-associated genes and MYC target genes (Supplementary Figure S2) . These findings strongly suggest that BCOR functions as a tumor suppressor in myeloid cells at least in part by affecting proliferation and self-renewal.
DISCUSSION
Mammalian hematopoiesis is a hierarchical process giving rise to all types of mature blood cells. Proliferation and differentiation are More mature stem cells and committed progenitor cells have higher proliferation rates. Although numerous factors involved in blood cell development have been identified, our knowledge of the process remains incomplete. In the present report, we discovered a previously unknown role of BCOR in hematopoiesis. Our results strongly suggest that BCOR plays an important role in normal hematopoiesis by contributing to the regulation of myeloid cell proliferation and differentiation. Global microarray and qRT-PCR uncovered expression of numerous genes that were altered in the Bcor mutant cells, several of which are implicated in myeloid differentiation (e.g. Cebpa and Cebpe). Importantly, our results showed that BCOR is a repressor of HoxA cluster of genes (HoxA5, HoxA7 and HoxA9) in myeloid cells (Figures 3b, c and 4f) . Knockdown of HoxA5, HoxA7 and HoxA9 significantly decreased the clonogenic growth of Bcor mutant and wild-type cells (Figures 3e  and f) , demonstrating the Hox genes, as targets of BCOR, played an important role in mediating BCOR's function in regulating myeloid cell proliferation. Similarly, a recent study demonstrated that knockdown of Pcgf1, another PRC1.1 complex component, in Lin − HSC also upregulated the expression of Hox genes and enhanced hematopoietic cell proliferation. 32 Furthermore, overexpression of HoxA4, HoxA9 and HoxA10 in Lin − HSC cells increased their plating capacity in methylcellulose. 44 In vivo, overexpression of HoxA9 and HoxA10 increased the pool of HSCs and myeloid progenitor cells and leads to late-onset leukemia. 45, 46 These finding demonstrate the important role of Hox genes in self-renewal of hematopoietic cells. Thus, upregulation of HoxA genes upon Bcor loss is likely responsible at least, in part, for the extended clonogenic growth of Bcor mutant hematopoietic stem/progenitor cell in replating assays.
BCOR is a component of the PRC1.1 transcriptional repressive complex which also includes RING1A/B, YAF2/RYBP, PCGF1 and KDM2B. 16, 17 RING1B is the E3 ubiquitin ligase that functions as the catalytic core of PRC1 complexes and is responsible for monoubiquitylation of H2A at position 119 (H2AK119ub). 23, 24 H2A ubiquitination activity of the PRC1 complex is a crucial step to mediate PRC1-dependent repression of differentiation-related genes to maintain ES cell identity. 47 Since PcG proteins are known repressors of Hox genes, we hypothesized that loss of BCOR may disrupt the activity of the PRC1.1 complex and lead to upregulation of a subset of genes known to be repressed by the PRC1 complex containing RING1B. Results showed that mutation of Bcor in murine myeloid cells was associated with a decrease in RING1B protein levels, while Ring1b mRNA levels remained unchanged. Western blot analysis showed that the global monoubiquitin level of H2AK119 was unchanged in the Bcor mutant cells. However, ChIP-quantitative PCR revealed that H2AK119ub levels at the promoters of HoxA5, HoxA7 and HoxA9 were significantly decreased in Bcor mutant cells. These results offer a mechanistic explanation for how BCOR regulates gene expression in myeloid cells, wherein loss of BCOR is associated with the loss of ubH2A at specific promoters without altering global ubH2A levels. Upregulation of HOXA9 gene was also detected in MDS patient samples with BCOR loss-of-function mutations (Figure 7d ).
MDS is a heterogeneous group of clonal BM disorders that predominate in the elderly. Often at the time of diagnosis, clonal expansion has replaced the normal hematopoietic cells. Unlike AML, MDS cells retain their ability to differentiate to mature myeloid blood cells, albeit often with various abnormalities. 48, 49 Thus, while the clonal population of MDS cells continues to expand in the BM, patients paradoxically experience variable cytopenias due to excessive cell death. 50 Loss of BCOR facilitates this phenotype by allowing an expanded marrow of hematopoietic cells at all stages of differentiation. Truncating mutations of BCOR are independently associated with a worse overall survival (OS) in MDS and a higher cumulative incidence of AML transformation. 9 MDS can progress to AML which has a nearly complete block of differentiation. MDS cells with BCOR loss-offunction likely acquire additional mutations resulting in a block in differentiation. Interestingly in MDS and AML, BCOR mutations associate preferentially with a group of molecular aberrations including RUNX1 and DNMT3A mutations. 9, 10 However, the exact role of BCOR in leukemia transformation awaits further studies.
In summary, our data suggest that BCOR plays an important role in normal hematopoiesis by contributing to the regulation of myeloid cell proliferation and differentiation. With loss of Bcor enhanced proliferation of more mature progenitor cells occurs, allowing increased production of mature myeloid cells. Functionally, BCOR appears to play a critical role in determining H2A ubiquitination levels and PcG proteins recruitment to promoters of lineagespecific genes to repress their expression. We hypothesize that loss of BCOR provides both a clonal growth advantage of the MDS clone, which when combined with additional mutations, can result in neoplastic transformation.
